PER-014-06已完成未知
Phase III Trial of the Analog Administration of the LHRH during Chemotherapy to Reduce Ovarian Failure by Chemotherapy in Patients with Early-Stage Breast Cancer with Negative Hormone Receptors
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2006年5月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1. Patients must be menopausal women with histologically confirmed diagnosis of Operable Invasive Breast Cancer stage I, II or IIA.
- •2. Patients should have tumors with hormone receptors positive for estrogen and progesterone.
- •3. Patients must be 18 to 50 years of age.
- •4. The treatment plan for patients is 3 to 8 months of standard chemotherapy with anthracycline or non-anthracycline agents as adjuvants or neoadjuvants.
- •5. Patients receiving chemotherapy in the preoperative stage should have planned to receive additional chemotherapy in the postoperative stage.
- •6. Patients receiving post-surgical chemotherapy should register before 84 days after the final surgery required for the proper treatment of the primary tumor.
- •7. Patients recruited in S0221 are eligible for this study.
- •8. Patients must have a physical status of 0 to 2 by Zubrod criteria.
- •9. All patients must be informed about the research nature of this study and must sign and give their consent.
排除标准
- •1. Patients must not have received chemotherapy for breast cancer or for any condition.
- •2. Patients must not have received estrogen or antiestrogens in the last 3 months. selective modulators of estrogen receptors, aromatase inhibitors or another hormonal form of contraception.
- •3. They must not have previous malignancy.
- •4. Women who are pregnant or breastfeeding can not participate.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit DeficiencyCongenital FXIII A-subunit DeficiencyMedDRA version: 13.1 Level: PT Classification code 10016083 Term: Factor XIII deficiency System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-016869-28-GBovo Nordisk A/S6
进行中（未招募）
1 期
Clinical trial of a new protocol of lung maturation by administration of corticoids in twin pregnancy patients with threatened preterm birth treated by Atosiban : administration of 3 doses of betamethasone (12 mg) in 18 hours apart, rather than 2 doses of betamethasone (12 mg) in 24 hours apart as used usually, to decrease the risk of respiratory distress syndrome at the newborn childrePremature delivery in twin pregnanciesMedDRA version: 19.1Level: LLTClassification code 10028244Term: Multiple pregnancy affecting fetus or newbornSystem Organ Class: 100000004868MedDRA version: 19.1Level: LLTClassification code 10036564Term: Pregnancy multipleSystem Organ Class: 100000004868EUCTR2016-003603-61-BE50
招募中
3 期
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.JPRN-jRCT1080224903ovartis Pharma. K.K.200
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-FIMSD Finland20,300
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-DEMerck & Co., Inc.20,300